NCT00472771撤回2 期
A Phase II, Open-label Study of INNO-206 in Patients With Recurrent Extensive Small Cell Lung Cancer After First-line Platinum-based Therapy
CytRx14 个研究点 分布在 1 个国家开始时间: 2008年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 试验地点
- 14
- 主要终点
- To determine the objective overall response rate (OR; complete [CR] and partial [PR] responses).
研究概览
简要总结
The purpose of this study is to determine whether INNO-206 is effective in the treatment of small cell lung cancer.
详细描述
This is a phase II, open-label, prospective, multicenter, single-arm study of INNO 206 in adult patients with recurrent extensive small cell lung cancer sensitive to first-line platinum-based therapy. The primary objective of the study is to determine the objective overall response rate. Secondary objectives include evaluating the treatment-related toxicities in this patient population and determining the pharmacokinetic (PK) profile of INNO-206 in a minimum of 12 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be ≥18 years old.
- •Have a histologically or cytologically confirmed diagnosis of recurrent extensive small cell lung cancer (SCLC) at the time of enrollment into the study.
- •Have responded to first-line platinum-based chemotherapy, but progressed or relapsed ≥60 days after completion of first-line therapy.
- •Have measurable disease defined by RECIST.
- •Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤
- •Have an estimated life expectancy of ≥4 weeks.
- •Be male or non-pregnant, non-lactating female patients. Patients who are fertile must agree to use an effective barrier method of birth control to avoid pregnancy while on therapy and for 90 days following the discontinuation of the study medication.
- •Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study medication (if patient is a female of childbearing potential).
- •Have adequate organ function.
排除标准
- •Are pregnant or lactating.
- •Have received prior anthracycline therapy.
- •Have participated in any investigational drug study within 30 days prior to study entry.
- •Have received radiotherapy within 2 weeks of treatment in this study.
- •Have not recovered from acute toxicity of all previous therapy prior to enrollment.
- •Have a history of a malignancy other than SCLC. Exceptions to this include: curatively treated nonmelanomatous carcinoma of the skin or in situ carcinoma of the cervix, or prior low-grade, localized prostate cancer (Gleason score ≤6); or a history of another malignancy that was curatively treated and no evidence of recurrence for a minimum of 5 years.
- •Have symptomatic central nervous system (CNS) metastases.
- •Have any concurrent severe or uncontrolled medical disease (such as active systemic infection, hypertension, congestive heart failure ≥NYHA Grade II, myocardial infarction within 6 months before study start, severe rhythm disturbances, etc.) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- •Have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.
- •Have received radiotherapy with >25% involvement of the bone marrow within 6 weeks prior to study start.
- •Have a known hypersensitivity to doxorubicin, 5% D-(+)-sucrose, 10 mM sodium phosphate, and/or 0.3% N-acetyltryptophane.
结局指标
主要结局
To determine the objective overall response rate (OR; complete [CR] and partial [PR] responses).
次要结局
- To determine time to progression.
- To determine progression-free survival.
- To determine the rates of stable disease and progressive disease.
- To determine overall survival.
- To evaluate the treatment-related toxicities in this patient population.
- To determine the pharmacokinetic profile of INNO-206 in a minimum of 12 patients.
研究者
研究点 (14)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic LeukemiaChronic Myeloid LeukemiaAcute Lymphocytic LeukemiaNCT00352677CytRx100
撤回
2 期
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic SyndromeAcute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)NCT01520805Cornerstone Pharmaceuticals
招募中
1 期
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsMetastatic Uveal MelanomaOther Solid TumorsColorectal CancerCutaneous MelanomaNCT03947385IDEAYA Biosciences336
终止
2 期
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell LymphomaMantle Cell LymphomaNCT00843050Piramal Enterprises Limited13
已完成
1 期
A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIVHIV-1-infectionNCT05828095National Institute of Allergy and Infectious Diseases (NIAID)20